# Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization

> **NCT02762266** · PHASE3 · TERMINATED · sponsor: **Stanford University** · enrollment: 13 (actual)

## Conditions studied

- Child-Pugh Class A
- Child-Pugh Class B
- Recurrent Hepatocellular Carcinoma

## Interventions

- **RADIATION:** Stereotactic Body Radiation Therapy
- **PROCEDURE:** Transarterial Chemoembolization
- **DRUG:** embolic agent
- **DRUG:** lipiodol

## Key facts

- **NCT ID:** NCT02762266
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-27
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Business decision - funding
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02762266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02762266, "Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02762266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*